Huang Lanlan, Chen Jian, Cao Peiqiu, Pan Haitao, Ding Chen, Xiao Tiancun, Zhang Pengfei, Guo Jiao, Su Zhengquan
Key Research Center of Liver Regulation for Hyperlipidemia SATCM/Class III Laboratory of Metabolism SATCM, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou 510006, China.
Inorganic Chemistry Laboratory, Oxford University, South Parks Road, OX1 3QR Oxford, UK.
Mar Drugs. 2015 Apr 30;13(5):2732-56. doi: 10.3390/md13052732.
OBJECTIVE: This study is to evaluate the anti-obese effects of glucosamine (GLC) and chitosan oligosaccharide (COS) on high-fat diet-induced obese rats. METHODS: The rats were randomly divided into twelve groups: a normal diet group (NF), a high-fat diet group (HF), Orlistat group, GLC high-, middle-, and low-dose groups (GLC-H, GLC-M, GLC-L), COS1 (COS, number-average molecular weight ≤1000) high-, middle-, and low-dose groups (COS1-H, COS1-M, COS1-L), and COS2 (COS, number-average molecular weight ≤3000) high-, middle-, and low-dose groups (COS2-H, COS2-M, COS2-L). All groups received oral treatment by gavage once daily for a period of six weeks. RESULTS: Rats fed with COS1 gained the least weight among all the groups (P < 0.01), and these rats lost more weight than those treated with Orlistat. In addition to the COS2-H and Orlistat groups, the serum total cholesterol (CHO) and low-density lipoprotein cholesterol (LDL-C) levels were significantly reduced in all treatment groups compared to the HF group (P < 0.01). The various doses of GLC, COS1 and COS2 reduced the expression levels of PPARγ and LXRα mRNA in the white adipose tissue. CONCLUSIONS: The results above demonstrated that GLC, COS1, and COS2 improved dyslipidemia and prevented body weight gains by inhibiting the adipocyte differentiation in obese rats induced by a high-fat diet. Thus, these agents may potentially be used to treat obesity.
目的:本研究旨在评估氨基葡萄糖(GLC)和壳寡糖(COS)对高脂饮食诱导的肥胖大鼠的抗肥胖作用。 方法:将大鼠随机分为十二组:正常饮食组(NF)、高脂饮食组(HF)、奥利司他组、GLC高、中、低剂量组(GLC-H、GLC-M、GLC-L)、COS1(壳寡糖,数均分子量≤1000)高、中、低剂量组(COS1-H、COS1-M、COS1-L)以及COS2(壳寡糖,数均分子量≤3000)高、中、低剂量组(COS2-H、COS2-M、COS2-L)。所有组均通过灌胃进行每日一次的口服治疗,为期六周。 结果:在所有组中,喂食COS1的大鼠体重增加最少(P < 0.01),且这些大鼠比接受奥利司他治疗的大鼠体重减轻更多。除COS2-H组和奥利司他组外,与HF组相比,所有治疗组的血清总胆固醇(CHO)和低密度脂蛋白胆固醇(LDL-C)水平均显著降低(P < 0.01)。不同剂量的GLC、COS1和COS2降低了白色脂肪组织中PPARγ和LXRα mRNA的表达水平。 结论:上述结果表明,GLC、COS1和COS2通过抑制高脂饮食诱导的肥胖大鼠的脂肪细胞分化,改善了血脂异常并防止体重增加。因此,这些药物可能潜在地用于治疗肥胖症。
Biomed Pharmacother. 2017-5-13
Int J Mol Sci. 2025-2-13
Mar Drugs. 2024-6-21
Food Sci Biotechnol. 2024-3-8
Polymers (Basel). 2023-10-1
Gene. 2014-10-25
J Agric Food Chem. 2014-2-14
Nucleic Acids Res. 2013-11-7
Int J Nanomedicine. 2012-7-27